ADVA
11.9.2019 09:02:11 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Inoventica has selected its FSP 3000 platform to meet soaring data demand from enterprise and carrier customers. Inoventica, one of Russia’s leading IT service providers and data center operators, will leverage the solution to boost the capacity of its backbone network to 100Gbit/s and beyond. The new fully redundant infrastructure leverages ADVA’s QuadFlex™ line card and OpenFabric™ cross-connect – two technologies optimized for efficiency and complete flexibility. ADVA’s Select partner, the IT solution specialist Zettaline is also playing a key role in facilitating the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190911005024/en/
“ADVA’s technology enables us to take the next step with our infrastructure while also leveraging maximum value from our existing network. With this deployment, we can flexibly respond to soaring data requirements and help our customers to unleash their full potential,” said Vitaly Slizen, CEO, Inoventica. “The ADVA FSP 3000 delivers several key efficiencies from low latency to optimized bandwidth utilization. And the FSP 3000 OpenFabric™ empowers us to cost-effectively provide the data rates our customers need by aggregating 1Gbit/s and 10Gbit/s services onto 100Gbit/s wavelengths. Furthermore, its openness means we can reap the benefits of unlimited innovation cycles in the future.”
Designed for scalability and bandwidth optimization, the ADVA FSP 3000 ensures that Inoventica’s new infrastructure offers superb efficiency. It enables significant energy savings and, with its 1RU footprint, occupies very little rack space. Using ADVA FSP 3000 QuadFlex™ technology, the solution will transport 100Gbit/s data loads over distances stretching to 2,000km across the Moscow metropolitan area. By enabling greater spectral efficiency, QuadFlex™ delivers extended reach without any need for signal regeneration. Also key is the ADVA FSP 3000 OpenFabric™ , which creates a distributed architecture, enabling Inoventica to simply and efficiently aggregate lower-speed services.
“We’re proud that Russia’s largest cloud service provider has chosen to harness our technology and expertise. Together with our partner Zettaline, we’ve built a solution that efficiently expands Inoventica’s infrastructure and provides the tools it needs to address today’s key challenges,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “The new fully redundant solution is protected, flexible and extremely cost-efficient. It also meets all of Inoventica’s density, security and energy requirements. Furthermore, thanks to the modular, scalable design of our FSP 3000 platform and the ongoing support of our team, Inoventica is free to plan an exciting roadmap for further development in the future.”
“This deployment is going to bring substantial benefits to a great number of Russian enterprises and we’re proud to be playing such a big part in helping Inoventica take this leap forward. Working closely with our friends at ADVA, we’ve created a transport system that squeezes maximum value from Inoventica’s existing resources while enabling the flexibility and capacity necessary for the 5G and IoT era,” said Alexander Hochmuth, shareholder representative, Zettaline Ltd. “As a team, ADVA and Zettaline provide both global knowledge and local expertise. Together, we’ve designed an open, disaggregated and completely future-proof solution that meets all of Inoventica’s needs and ambitions.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com .
About Inoventica
INOVENTICA Group of Companies is the first Russian IT-operator that has been implementing projects based on innovative ICT Infrastructure of international scale based on cloud computing technologies since 1999. Partners and clients of the INOVENTICA Group of Companies are more than 5 thousand B2C subscribers, more than 1000 corporate clients (B2B), 48 national and international telecom operators. www.invs.ru
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190911005024/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
